GL1X · GenesisL1 explorer

Research workbench

Crystal structure of the human pcaf bromodomain in complex with compound 12

Analyse Crystal structure of the human pcaf bromodomain in complex with compound 12 in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
6J3O
Type
protein
Length
211 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Histone acetyltransferase KAT2B
EC
2.3.1.48, 2.3.1.57
UniProt
Q92831
Ligands
B4L
Pockets
4 · best druggability 0.65

Structure

x-ray diffraction · 2 distinct chains · 64% helix, 0% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AHistone acetyltransferase KAT2B (EC 2.3.1.48, 2.3.1.57)protein10666% helix, 0% strandQ92831
BHistone acetyltransferase KAT2B (EC 2.3.1.48, 2.3.1.57)protein10563% helix, 0% strandQ92831

Ligands and binding sites

  • B4L · 3-methyl-2-[[(3~{R})-1-methylpiperidin-3-yl]amino]-5~{H}-pyrrolo[3,2-d]pyrimidin-4-one · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14050.650.7844empty
21080.570.8521B4L
31070.530.8219B4L
4550.340.7813empty

Interfaces

1 interface between chains.

  • A–B · 788 Ų buried · 9 hydrogen bonds · protein-protein

Compared structures

  • 6J3O · Crystal structure of the human PCAF bromodomain in complex with compound 12 · the same entry in another collection · chain A against A, TM-score 1.00
  • Q92831 · AlphaFold monomer V2.0 prediction for histone acetyltransferase KAT2B (Q92831) · a predicted model of the same protein · chain B against A, TM-score 0.98

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.